Advertisement


Banu Arun, MD, on Fine-Tuning Risk Assessment and Risk Reduction in Breast Cancer

2021 San Antonio Breast Cancer Symposium

Advertisement

Banu Arun, MD, of The University of Texas MD Anderson Cancer Center, discusses a session she moderated that included discussion of how exercise and diet may reduce the risk of breast cancer, and emerging non-endocrine treatments that may help prevent the disease.



Related Videos

Breast Cancer

Michael Gnant, MD, on HR-Positive, HER2-Negative Early Breast Cancer: Trial Results With Palbociclib Treatment

Michael Gnant, MD, of the Medical University of Vienna, discusses phase III findings from the PALLAS study, which showed that adding 2 years of palbociclib to ongoing adjuvant endocrine therapy did not improve survival for patients with stage II to III hormone receptor–positive, HER2-negative early breast cancer. Dr. Gnant also talks about whether any correlative studies hint at patient subgroups that this regimen may benefit (Abstract GS1-07) .

Breast Cancer

Ann H. Partridge, MD, MPH, on SABCS Meeting Highlights: Expert Perspective

Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, discusses what she considers to be the most notable presentations at the 2021 San Antonio Breast Cancer Symposium. They include the focus on early-stage disease, especially in the TEXT/SOFT, RxPonder, and KEYNOTE-522 trials, as well as abstracts from the Early Breast Cancer Trialists’ Collaborative Group; and new data and novel therapeutics in the advanced setting.

Breast Cancer
Immunotherapy

Elizabeth A. Mittendorf, MD, PhD, on Making Strides in Managing Triple-Negative Breast Cancer

Elizabeth A. Mittendorf, MD, PhD, of Dana-Farber Brigham and Women’s Cancer Center, discusses the progress made in recent years treating patients with triple-negative breast cancer (TNBC), including approval of the immunotherapy agents pembrolizumab and sacituzumab govitecan-hziy, a new standard of care in the preoperative setting for early-stage disease, as well as a better understanding of the biology of TNBC and its heterogeneity.

Breast Cancer
Immunotherapy

Javier Cortés, MD, PhD, on Previously Untreated Triple-Negative Breast Cancer: Pembrolizumab Plus Chemotherapy

Javier Cortés, MD, PhD, of the International Breast Cancer Center, discusses the final phase III results of KEYNOTE-355, which showed that pembrolizumab and chemotherapy improved overall and progression-free survival, compared with placebo and chemotherapy, for patients with previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (Abstract GS1-02 ).

Breast Cancer
Immunotherapy

Sara A. Hurvitz, MD, on HER2-Positive Metastatic Breast Cancer: T-DXd vs T-DM1

Sara A. Hurvitz, MD, of the University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses phase III findings from the DESTINY-Breast03 trial, which compared ado-trastuzumab deruxtecan (T-DXd) with standard-of-care trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer. T-DXd showed superior progression-free survival across subgroups of patients previously treated with trastuzumab and a taxane, including those with brain metastases (Abstract GS3-01).

Advertisement

Advertisement



Advertisement